Legionella News and Research

RSS

UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

UCB, a global biopharmaceutical leader, and Dermira, Inc., a privately held US-based dermatology company, announced today that they have entered into an exclusive licensing agreement for the development and future commercialization of Cimzia (certolizumab pegol) in dermatology.

3 Jul 2014

Legionnaires may be able to grow in windshield washer fluid

A form of bacteria responsible for respiratory illness, including the deadly pneumonia known as Legionnaire's disease, may be able to grow in windshield washer fluid and was isolated from nearly 75% of school buses tested in one district in Arizona, according to research presented today at the annual meeting of the American Society for Microbiology.

19 May 2014

UCB announces results from PRECiSE clinical trial of Cimzia in patients with Crohn's disease

UCB announced today results from the PRECiSE 3 7-year open label extension clinical trial of Cimzia (certolizumab pegol), the longest continuous trial of an anti-TNF therapy evaluating long-term safety in Crohn's disease.

6 May 2014

Studies indicate that harvested rainwater frequently harbors pathogens

South Africa has been financing domestic rainwater harvesting tanks in informal low-income settlements and rural areas in five of that nation's nine provinces. But pathogens inhabit such harvested rainwater, potentially posing a public health hazard, especially for children and immunocompromised individuals, according to a team from the University of Stellenbosch.

27 Feb 2014

New technique detects bacterium that causes Legionnaires’ disease

The bacterium that causes Legionnaires’ disease remains difficult to track. French researchers have now developed a new technique that should allow living representatives of this dangerous pathogen to be detected much more quickly than with conventional methods. As they report in the journal Angewandte Chemie, samples are exposed to an azide-modified compound that the pathogen specifically incorporates into its shell, which is made of saccharide units. A fluorescent marker attached to the azide groups is used to identify the pathogen.

24 Jan 2014

Hot water contamination in hospital taps threatens patient safety

New research finds significantly higher levels of infectious pathogens in water from faucet taps with aerators compared to water from deeper in the plumbing system. Contaminated water poses an increased risk for infection in immunocompromised patients.

22 Jan 2014

Protein responsible for excretion of copper in body cells utilizes unique transport mechanism

We are fundamentally dependent on the presence of copper in the cells of the body. Copper is actually part of the body's energy conversion and protective mechanisms against oxygen radicals, as well as part of the immune system, and it also has great importance for the formation of e.g. hormones and neurotransmitters.

28 Dec 2013

New AquaLyse ionization technology prevents legionella and related disease outbreaks

With growing reports of Legionella and related Legionnaires' disease outbreaks in the USA, Canada and around the world, ProCare Water Treatment Inc. today announces its newest "AquaLyse® ICR-820" medical and commercial grade copper-silver ionization chamber cells.

11 Dec 2013

Probiotics may help keep bad germs at bay

Microbes are everywhere - thousands of species are in your mouth, and thousands are in a glass of tap water. The ones in your mouth are mostly harmless - as long as you brush and floss so they don't form a biofilm that allows gum disease a path into the blood stream.

4 Nov 2013

FDA approves Cimzia for treatment of adults with active ankylosing spondylitis

UCB announced today that the U.S. Food and Drug Administration has approved Cimzia (certolizumab pegol) for the treatment of adults with active ankylosing spondylitis.

18 Oct 2013

FDA approves Cimzia (certolizumab pegol) for active psoriatic arthritis

UCB announced today that the U.S. Food and Drug Administration has approved Cimzia (certolizumab pegol) for the treatment of adult patients with active psoriatic arthritis.

30 Sep 2013

AOAC international certification validates Biótica's Legipid Legionella Fast Detection Test

The AOAC international certification has validated Biótica's MP4-Hunter. The system developed by the company settled at the Science Park in the Universitat Jaume I de Castellón (Spain) enables to perform up to 40 Legionella tests per analyst in an hour.

18 May 2013

Cempra demonstrates solithromycin's potential against urogenital infections at ECCMID

Cempra, Inc., a clinical-stage pharmaceutical company focused on developing differentiated antibiotics to meet critical medical needs in the treatment of bacterial infections, today announced that it will present data at the European Congress of Clinical Microbiology and Infectious Diseases in Berlin, demonstrating solithromycin's potential to treat urogenital infections and combat challenging pathogens such as enterococci and Legionella pneumophila.

29 Apr 2013

New treatment options for influenza

The flu is caused by an infection with the influenza virus, which mainly attacks the upper respiratory tract - the nose, throat and bronchi and rarely also the lungs. According to the World Health Organization, around five to 15 percent of the population are affected by upper respiratory tract infections during seasonal flu outbreaks, and between 250 000-500 000 people die of the illness every year.

29 Apr 2013

UCB seeks FDA and EMA marketing authorization for Cimzia to treat active psoriatic arthritis

UCB announced today two new regulatory filings with the US Food and Drug Administration (FDA) and with the European Medicines Agency (EMA) to extend the marketing authorization for Cimzia (certolizumab pegol) for the treatment of adult patients with active psoriatic arthritis (PsA) and for adult patients with active axial spondyloarthritis (axSpA).

20 Feb 2013

ACE Environmental Advisory explores potential risks of mold and legionella at healthcare facilities

The ACE Group today announced the release of an environmental advisory entitled, "Legionella and Mold: Construction and Renovation Risks at Healthcare Facilities," which explores the potential risks of pollutants, such as mold and legionella, that hospitals and healthcare facilities can experience during renovation or construction projects.

3 Nov 2012

Positive results from Cempra's IV solithromycin Phase 1 study

Cempra, Inc., a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced results of its Phase 1 study of intravenous (IV) solithromycin in healthy subjects. The study demonstrated that IV solithromycin was well tolerated, showed a favorable pharmacokinetic profile (PK) and achieved relevant plasma concentrations.

8 Oct 2012

Tips to prevent illness in crowds

Massive crowds from around the globe will mingle in London during the Olympics, and that means a world-class array of germs will mix with them. Mayo Clinic infectious diseases expert Gregory Poland, M.D., offers several tips for avoiding illness when you are around lots of people, whether at the Olympics, a professional football game, convention, arena concert or other major event.

26 Jul 2012

Caspase-11 enzyme plays an important role in Legionella infection

New research shows that an enzyme that has long been considered relatively useless to the immune response instead has an important role in setting up immune cells to kill infection-causing bacteria.

13 Jun 2012

Nephros granted rights to market products based on Medica's Medisulfone ultrafiltration technology

Nephros, Inc., a medical device company developing and marketing filtration products for therapeutic applications, infection control, and advanced water purification solutions, today announced that the company has entered into a strategic license and supply agreement with Medica S.p.A.

23 Apr 2012